Medicamen Biotech Ltd
MEDICAMEQMedicamen Biotech Ltd
MEDICAMEQPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
91.76 | 3.24 | 0.19% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.90 | 6.61 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
MEDICAMEN Biotech is engaged in manufacturing of pharmaceutical formulations.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 126.26 | 127.44 | 113.47 | 117.17 | 143.33 | 181.64 | 183.88 | |||||||
Raw Materials | 81.95 | 80.45 | 68.42 | 55.69 | 81.80 | 104.70 | 162.21 | |||||||
Power & Fuel Cost | 2.11 | 2.90 | 2.68 | 5.86 | 5.67 | 7.14 | ||||||||
Employee Cost | 8.09 | 9.52 | 9.00 | 14.50 | 20.15 | 29.07 | ||||||||
Selling & Administrative Expenses | 5.30 | 5.16 | 4.14 | 7.79 | 7.90 | 14.95 | ||||||||
Operating & Other expenses | 7.69 | 8.00 | 8.80 | 7.51 | 1.00 | -0.07 | ||||||||
EBITDA | 21.12 | 21.41 | 20.43 | 25.82 | 26.81 | 25.85 | 21.67 | |||||||
Depreciation/Amortization | 2.21 | 2.50 | 2.52 | 5.77 | 6.37 | 7.09 | 7.95 | |||||||
PBIT | 18.91 | 18.91 | 17.91 | 20.05 | 20.44 | 18.76 | 13.72 | |||||||
Interest & Other Items | 1.38 | 0.93 | 1.51 | 1.94 | 3.39 | 5.67 | 4.29 | |||||||
PBT | 17.53 | 17.98 | 16.40 | 18.11 | 17.05 | 13.09 | 9.43 | |||||||
Taxes & Other Items | 5.50 | 4.69 | 4.27 | 3.20 | 2.20 | 2.14 | 2.11 | |||||||
Net Income | 12.03 | 13.29 | 12.13 | 14.91 | 14.85 | 10.95 | 7.32 | |||||||
EPS | 10.28 | 11.11 | 9.93 | 12.20 | 11.94 | 8.63 | 5.76 | |||||||
DPS | 1.00 | 0.50 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |||||||
Payout ratio | 0.10 | 0.04 | 0.10 | 0.08 | 0.08 | 0.12 | 0.17 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Medicamen Biotech Ltd | 61.34 | 3.24 | 0.19% |
Sun Pharmaceutical Industries Ltd | 45.10 | 6.44 | 0.75% |
Cipla Ltd | 29.41 | 4.52 | 0.87% |
Torrent Pharmaceuticals Ltd | 68.50 | 16.55 | 0.84% |
Price Comparison
Compare MEDICAMEQ with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
MEDICAMEQ has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.19%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.89 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2024
Dividend/Share
₹1.00
Ex DateEx Date
Sep 19, 2024
Cash Dividend
Ex DateEx DateSep 20, 2023
Dividend/Share
₹1.00
Ex DateEx Date
Sep 20, 2023
Cash Dividend
Ex DateEx DateSep 19, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Sep 19, 2022
Cash Dividend
Ex DateEx DateSep 16, 2021
Dividend/Share
₹1.00
Ex DateEx Date
Sep 16, 2021
Cash Dividend
Ex DateEx DateSep 17, 2020
Dividend/Share
₹0.50
Ex DateEx Date
Sep 17, 2020
Net profit of Medicamen Biotech declined 3.31% to Rs 1.46 crore in the quarter ended September 2024 as against Rs 1.51 crore during the previous quarter ended September 2023. Sales rose 2.76% to Rs 44.74 crore in the quarter ended September 2024 as against Rs 43.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales44.7443.54 3 OPM %11.8710.66 - PBDT4.564.29 6 PBT1.962.46 -20 NP1.461.51 -3 Powered by Capital Market - Live
Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Medicamen Biotech announced that the Annual General Meeting (AGM) of the company will be held on 26 September 2024.Powered by Capital Market - Live
Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Medicamen Biotech’s USFDA filing sparks 5.12 per cent surge in shares
Medicamen Biotech gains on successful ANDA filing for Bortezomib injections
Medicamen Biotech announces debut in domestic pharma sector
Aarvee Denims & Exports Ltd leads gainers in ‘B’ group
Medicamen Biotech signs CDMO agreement with Vital Pharma Nordic
Medi Caps gets approval under RERA for Real Estate Project ‘Medicaps Business Park’
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 7.54%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.06% to 0.05%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -1.86%, vs industry avg of 15.27%